Estrella Immunopharma, Inc.
ESLA
$0.94
-$0.0295-3.04%
NASDAQ
| 06/30/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -163.50% | 14.54% | 14.54% | -741.55% | -741.55% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -- | -- | -- | -- |
| Change in Net Operating Assets | 236.05% | -68.32% | -68.32% | 197.20% | 197.20% |
| Cash from Operations | 10.97% | -660.72% | -660.72% | 93.12% | 93.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | 44.32% | 44.32% | -221.40% | -221.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,540.68% | 44.32% | 44.32% | -221.40% | -221.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 280.68% | -321.41% | -321.41% | 86.99% | 86.99% |